| Literature DB >> 31809899 |
Sakthi Rajendran1, Florence Anquetil1, Estefania Quesada-Masachs1, Madeleine Graef1, Nathaly Gonzalez1, Sara McArdle1, Tiffany Chu1, Lars Krogvold2, Knut Dahl-Jørgensen3, Matthias von Herrath4.
Abstract
IL-6 is a pro-inflammatory cytokine upregulated in some autoimmune diseases. The role of IL-6 in the development of type 1 diabetes (T1D) is unclear. Clinical studies are investigating whether tocilizumab (anti-IL-6 receptor) can help preserve beta cell function in patients recently diagnosed with T1D. However, in some rodent models and isolated human islets, IL-6 has been found to have a protective role for beta cells by reducing oxidative stress. Hence, we systematically investigated local tissue expression of IL-6 in human pancreas from non-diabetic, auto-antibody positive donors and donors with T1D and T2D. IL-6 was constitutively expressed by beta and alpha cells regardless of the disease state. However, expression of IL-6 was highly reduced in insulin-deficient islets of donors with T1D, and the expression was then mostly restricted to alpha cells. Our findings suggest that the implication of IL-6 in T1D pathogenesis might be more complex than previously assumed.Entities:
Year: 2019 PMID： 31809899 PMCID： PMC6961707 DOI： 10.1016/j.clim.2019.108320
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969